PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Cetuximab

Drugs in development · updated 30 October 2026

Cetuximab: clinical trials and development status

Other names and codes: Erbitux

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 29 June 2004

As of 30 October 2026 Cetuximab is in 209 active clinical trials (recruiting or ongoing, phases I–III) for 61 diseases. The most advanced phase is III.

209Active trials
IIIMost advanced phase
61Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Cetuximab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 61 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Colorectal neoplasmIII81NCT07775287
Head and neck squamous cell carcinomaIII39NCT06589804
Colonic neoplasmIII19NCT06997497
Head and neck neoplasmsIII16NCT02999087
MetastasisIII15NCT06064877
NeoplasmIII13NCT04607421
Rectal neoplasmIII11NCT06997497
Squamous cell carcinomaIII7NCT04892173
CarcinomaIII5NCT06589804
Hypopharyngeal NeoplasmsIII4NCT06589804
Laryngeal neoplasmIII4NCT06589804
Mouth NeoplasmsIII4NCT06589804
Oropharyngeal NeoplasmsIII4NCT07768189
Gastrointestinal neoplasmIII3NCT04607421
Laryngeal diseaseIII2NCT04590963
Colonic diseaseIII1NCT04607421
Digestive System DiseasesIII1NCT04607421
Digestive system neoplasmIII1NCT04607421
Gastrointestinal diseaseIII1NCT04607421
Intestinal diseaseIII1NCT04607421
Intestinal neoplasmIII1NCT04607421
Nasopharyngeal CarcinomaII–III1NCT05063552
Rectal diseaseIII1NCT04607421
Tongue neoplasmIII1NCT00956007
Non-small-cell lung carcinomaII22NCT07463677
Pancreatic neoplasmII12NCT07644559
Lung neoplasmII11NCT07463677
Breast neoplasmII6NCT05226871
Endometrial neoplasmI–II6NCT07020221
Ovarian neoplasmI–II4NCT04956640

Everything on Cetuximab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch